ArticleMicrobiology spectrum2025
Impact of obesity on the gut microbiome and inflammatory markers during SIV infection and antiretroviral therapy.
Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Dysbiosis and impaired gut barrier integrity contribute to chronic immune activation associated with both obesity and HIV infection. Given the increased incidence of obesity in people living with HIV, we explored the impact of obesity on the gut microbiome and microbial translocation (MT) biomarkers during HIV infection and antiretroviral therapy (ART). Lean and obese rhesus macaques were infected with simian immunodeficiency virus (SIV) and subsequently treated with ART. Obese animals exhibited higher initial MT and inflammation biomarkers that remained constant throughout the study, while lean animals exhibited significant increases in these biomarkers that approached levels observed in obese animals. Lean and obese animals exhibited similar observed amplicon sequence variants (ASVs) at baseline, with obese animals exhibiting reduced ASVs during acute SIV infection that rebounded after 39 weeks of ART treatment. Beta diversity differed between groups and was longitudinally altered in obese animals. Obese animals exhibited significant changes in differential abundance in four times as many bacterial genera compared to lean animals. Our finding that MT and inflammation biomarkers significantly changed in lean animals, while obese animals exhibited significant alterations in microbial diversity, suggests that microbiome changes and systemic inflammation may not directly correlate during SIV infection and ART.IMPORTANCEIn response to the obesity epidemic, the incidence of obesity at the time of HIV diagnosis has increased, but the impacts of pre-existing obesity throughout antiretroviral therapy (ART)-treated HIV infection remain underexplored. Both obesity and HIV infection have been associated with inflammatory and microbiome perturbations. Here, we utilized 16S rRNA amplicon sequencing and quantification of systemic inflammation markers to longitudinally characterize the fecal microbiome and systemic inflammation in lean and obese rhesus macaques throughout simian immunodeficiency virus (SIV) infection and ART. Lean animals exhibited marked increases in inflammatory markers corresponding with minimal gut microbiome perturbations throughout SIV infection and ART. In contrast, obese animals exhibited minimal inflammatory alterations corresponding with distinct differentially abundant fecal bacterial taxa throughout SIV infection and ART. Our results provide crucial insights into the interactions between pre-existing obesity, inflammation, and the gut microbiome that may aid in developing therapeutic strategies for obese individuals diagnosed with HIV.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.